Key facts
- This page summarizes Weiguo Ye's Form 4 filing for GYRE THERAPEUTICS, INC. (GYRE).
- 9 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 22 Jun 2026, 16:02.
Weiguo Ye - 09 Jun 2026 Form 4 Insider Report for GYRE THERAPEUTICS, INC. (GYRE)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- GYRE
- Reported as of
- 09 Jun 2026
- Net transaction value
- -$68,700
- SEC form
- 4
- Accepted by SEC
- 22 Jun 2026, 16:02:41 UTC
- Prior SEC filing
- 08 Jun 2026
- Next SEC filing
- 15 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Weiguo Ye
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Weiguo Ye filed Form 4 for GYRE THERAPEUTICS, INC. (GYRE) on 22 Jun 2026.
Change
- Previous filing in this sequence was filed on 08 Jun 2026.
- Current net transaction value: -$68,700.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001985496
Primary reporting owner
Ye Weiguo
- Relationship
- Chief Operating Officer
- Address
- C/O GYRE THERAPEUTICS, INC., 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO
- Signature
- /s/ Weiguo Ye
- Signature date
- 22 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GYRE
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,000
- Change %
- +0.43%
- Price
- $0.7500*
- Shares after
- 703,000
- Date
- 09 Jun 2026
- Ownership
- Direct
GYRE
transaction
Common Stock
Sale
- Transaction value
- $18,450
- Shares
- -3,000
- Change %
- -0.43%
- Price
- $6.15
- Shares after
- 700,000
- Date
- 09 Jun 2026
- Ownership
- Direct
GYRE
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +5,000
- Change %
- +0.71%
- Price
- $0.7500*
- Shares after
- 705,000
- Date
- 10 Jun 2026
- Ownership
- Direct
GYRE
transaction
Common Stock
Sale
- Transaction value
- $31,200
- Shares
- -5,000
- Change %
- -0.71%
- Price
- $6.24
- Shares after
- 700,000
- Date
- 10 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
GYRE
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,000
- Change %
- +0.43%
- Price
- $0.7500*
- Shares after
- 703,000
- Date
- 18 Jun 2026
- Ownership
- Direct
GYRE
transaction
Common Stock
Sale
- Transaction value
- $19,050
- Shares
- -3,000
- Change %
- -0.43%
- Price
- $6.35
- Shares after
- 700,000
- Date
- 18 Jun 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GYRE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -3,000
- Change %
- -0.36%
- Price
- $0.000000*
- Shares after
- 835,701
- Date
- 09 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,000
- Exercise price
- $0.7500
- Footnotes
- F2
GYRE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -5,000
- Change %
- -0.6%
- Price
- $0.000000*
- Shares after
- 830,701
- Date
- 10 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,000
- Exercise price
- $0.7500
- Footnotes
- F2
GYRE
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -3,000
- Change %
- -0.36%
- Price
- $0.000000*
- Shares after
- 827,701
- Date
- 18 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,000
- Exercise price
- $0.7500
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.20 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Footnote F2
These options are vested in full.